Table 7

mCRC treatment: GRADE recommendations

Quality of evidences (GRADE)RecommendationStrength of clinical recommendation
Very lowStarting a treatment for metastatic disease at the time of diagnosis, also without disease-related symptoms, is recommended. A wait-and-see period might be considered in well-selected cases (elderly, comorbidities, minimal tumour load) after an adequate evaluation of risks/benefits.62 63 Strong for
ModerateA maintenance treatment with bevacizumab±fluoropyrimidine can be considered in patients with mCRC after a first-line treatment with bevacizumab, after an adequate evaluation of risks/benefits and patient’s motivation.16 17 Conditional for
  • GRADE, Grading of Recommendations, Assessment, Development and Evaluations; mCRC, metastatic colorectal cancer.